LRR-Finder™ Platform

Harnessing an unprecedented synthetic library and phage display technology to rapidly generate Ccombodies—genetically engineered recombinant antibodies with exceptional stability and broad versatility.

Platform Overview

LRR-Finder™: Pioneering Ccombody Discovery Platform

At Protheragen, we have developed our proprietary Molecular Evolution Synthetic Library platform to generate Ccombodies by combining AI-informed synthetic libraries with phage display technology, enabling the development of high-affinity binders entirely in vitro without the need for animal immunization. A Gram-positive bacterial expression system allows for rapid, cost-effective large-scale production of endotoxin-free Ccombodies. With a compact single-chain scaffold of approximately 28–30 kDa and flexible structure, these molecules can be readily optimized for diverse research and industrial applications. These advantages position Ccombody as a versatile antibody platform serving the biotechnology industry—from research to diagnostics and therapeutics.

Disruptive Technology
Excellent Team
Diversified Pipeline
Customized Solutions

Platform Core

Ccombodies: Next-Generation Antibodies with Unmatched Stability and Versatility

Ccombody is inspired by variable lymphocyte receptors (VLRs) discovered in jawless vertebrates such as hagfish and lampreys in 2004, where leucine-rich repeat (LRR) domains provide a flexible scaffold for antigen recognition distinct from conventional antibodies. Building upon this biological blueprint, Protheragen established an unprecedented fully synthetic library—the Molecular Evolution Synthetic Library—with a theoretical diversity of approximately 10⁴¹. Leveraging this platform, we develop Ccombodies entirely in vitro, identifying more antigen-specific binders in 18 months than were discovered from natural VLRs and Repebodies over the past two decades. These engineered antibodies feature a compact, single-chain LRR scaffold of approximately 28–30 kDa, offering the following advantages:

Broad Antigen Recognition: Capable of binding diverse targets including proteins, viruses, peptides, and small molecules with high versatility.
High Affinity and Specificity: Engineered for exceptional binding strength and precise selectivity, enabling discrimination between closely related targets.
Large-Scale Production Capacity: Enables cost-effective, high-efficiency manufacturing suitable for industrial-scale applications.
Exceptional Stability: Maintains structural integrity and binding activity across a wide range of temperatures and pH conditions.
Versatile Applications: Readily adaptable for use across diagnostics, therapeutics, and functional material development.

Platform Advantages

Unique Advantages of the LRR-Finder™ Platform

Unrivaled Diversity & Exceptional Stability

Our LRR-Finder™ synthetic library achieves an unprecedented theoretical diversity of ~10⁴¹, enabling the discovery of more antigen-specific binders in just 18 months than were identified from natural LRR sources over the past two decades. The resulting Ccombodies feature a compact, single-chain LRR scaffold of approximately 28–30 kDa, conferring outstanding stability across a wide range of temperatures and pH conditions.

High Affinity & Specificity

By combining AI-informed library design with phage display technology, LRR-Finder™ rapidly evolves binders with exceptional affinity and specificity, capable of discriminating between highly similar targets where traditional antibodies often fail.

Cost-Effective, Endotoxin-Free Production

Utilizing a Gram-positive expression system, our platform enables rapid scale-up at low cost. Critically, this system yields products naturally free of endotoxins, eliminating a major safety concern for therapeutic and diagnostic applications.

Platform Application

Driving Innovation Across Research, Diagnostics, and Therapeutics

Advanced Diagnostics

Develop rapid, highly sensitive diagnostic kits for infectious diseases in human, animal, plant, and aquaculture settings. The exceptional stability of Ccombodies enables reliable performance in point-of-care tests under harsh environmental conditions.

Next-Generation Therapeutics

Address critical healthcare needs with innovative therapies, including overcoming antibiotic resistance, developing passive immunizations for infectious diseases, and creating novel treatments for oral, ocular, respiratory, immune, and oncological diseases.

Functional Biomaterials & Cosmeceuticals

Harness the binding specificity of Ccombodies to create functional ingredients for skin health and beyond. Applications include anti-aging and anti-inflammatory cosmetic ingredients, as well as functional additives for foods and animal feed.

Allergy Alleviation

Develop targeted solutions for allergy sufferers. Our stable Ccombodies can be engineered to specifically neutralize allergens from pets, dust mites, and pollen, offering a novel approach to allergy relief and management.

Research and Industrial Applications

Provide custom antibody development services tailored to specific research needs, along with a comprehensive protein analysis and purification platform to support diverse research and industrial applications.

Pipeline

Research & Development Pipeline

Projects	Target	Indication
LHT004	MRSA	Antibiotic-Resistant Infection
LHT006	SARS-CoV-2 Spike Protein	Respiratory Infection
LHT012	Dust Mite Allergen (Der p 1)	Allergic Rhinitis
LHT015	Fel d 1 (Cat Allergen)	Pet Allergy

Get in Touch with Us

FAQs

Frequently Asked Questions

Q1: What exactly is a Ccombody? A: A Ccombody is an engineered binding protein based on an LRR scaffold, inspired by the adaptive immune system of jawless vertebrates. Unlike traditional antibodies, Ccombodies are small (~28–30 kDa), single-chain, and exceptionally stable, enabling easier engineering and production.
Q2: What is the diversity of your synthetic library? A: Our proprietary LRR-Finder™ library achieves an unprecedented theoretical diversity of approximately 10⁴¹, providing a vast landscape to discover high-affinity binders against virtually any target.
Q3: Do you use animals in the development process? A: No. LRR-Finder™ is entirely animal-free. We utilize in vitro phage display technology to screen our synthetic library, eliminating the need for animal immunization and the associated time, variability, and ethical concerns.
Q4: How are Ccombodies produced, and are they safe for therapeutic use? A: We use a Gram-positive bacterial expression system, which does not produce endotoxins—a common contaminant in traditional E. coli systems. This ensures safe, cost-effective, and inherently therapeutic-grade production.
Q5: What types of targets can LRR-Finder™ address? A: Our platform is highly versatile. We have successfully developed Ccombodies against a wide range of targets, including proteins, viruses, peptides, and small molecules.